Evidence map›Paper›PMID 30782663›Full record

ArticlemBio2019

Ephrin Receptor A4 is a New Kaposi's Sarcoma-Associated Herpesvirus Virus Entry Receptor.

Jia Chen, Xianming Zhang, Samantha Schaller, Theodore S Jardetzky, Richard Longnecker

Open access · goldAbstract read
In one paragraph

Article in mBio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jia ChenDepartment of Microbiology and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Xianming ZhangDepartment of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Samantha SchallerDepartment of Microbiology and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Theodore S JardetzkyDepartment of Structural Biology, Stanford University School of Medicine, Stanford, California, USA.
Richard LongneckerDepartment of Microbiology and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA r-longnecker@northwestern.edu.ORCID 0000-0001-7175-6217
Northwestern University · USStanford University · US

Funding

Virology and Immunology Technology CoreP30AI117943 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Mohamed Abdel Mohsen · 2015 to 2026
$38.4M
Structural and Functional Studies of gp42 and HLA Class II in EBV EntryR01AI076183 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI JARDETZKY, THEODORE S, LONGNECKER, RICHARD M · 2008 to 2017
$4.6M
Structure and Function of EBV Protein Complexes that Trigger Epithelial Cell EntryR01AI137267 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI JARDETZKY, THEODORE S, LONGNECKER, RICHARD M · 2018 to 2022
$3.6M
NIAID NIH HHS P30 AI117943NIAID NIH HHS R01 AI076183NIAID NIH HHS R01 AI137267
6 · The paper itself

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) is a human gammaherpesvirus associated with the development of Kaposi's sarcoma (KS). KSHV target cells include endothelial cells, B cells, monocytes, epithelial cells, dendritic cells, macrophages, and fibroblasts. KSHV entry into target cells is a complex multistep process and is initiated by the binding and interaction of viral envelope glycoproteins with the cellular receptors. In the current studies, we have found that EphA4 promotes KSHV glycoprotein H/glycoprotein L (gH/gL)-mediated fusion and infection better than does ephrin A2 (EphA2) in HEK293T cells, indicating that EphA4 is a new KSHV entry receptor. To confirm that epithelial cells express EphA2 and EphA4, we analyzed the expression of EphA2 and EphA4 in epithelial cells, endothelial cells, B cells, monocytes, fibroblasts using RNA sequencing (RNA-seq) data analysis of existing data sets. We found that these cell types broadly express both EphA2 and EphA4, with the exception of monocytes and B cells. To confirm EphA4 is important for KSHV fusion and infection, we generated EphA2 and EphA4 single- and double-knockout cells. We found that both EphA2 and EphA4 play a role in KSHV fusion and infection, since EphA2-EphA4 double-knockout cells had the greatest decrease in fusion activity and infection compared to single-knockout cells. Fusion and infection of KSHV were rescued in the EphA2-EphA4 double-knockout cells upon overexpression of EphA2 and/or EphA4. EphA2 binds to both Epstein-Barr virus (EBV) and KSHV gH/gL; however, EphA4 binds only to KSHV gH/gL. Taken together, our results identify EphA4 as a new entry receptor for KSHV.

Indexed as

Virus InternalizationEndothelial CellsEphrin-A2Epithelial CellsFibroblastsGene Expression ProfilingGene Knockout TechniquesGenetic Complementation TestHEK293 CellsHerpesvirus 8, HumanHumansReceptor, EphA2Receptor, EphA4Receptors, VirusEPHA2 protein, humanEphrin-A2Receptor, EphA2Receptor, EphA4Receptors, VirusEphA4Eph receptorsgH/gLKaposi’s sarcoma-associated herpesvirusviral entry

Identifiers

PMID30782663
PMCPMC6381284
OpenAlexW2949838281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.